Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It operates through two segments, Intellectual Property Licensing and B2B Production. The company develops and out-licenses its DehydraTECH technology that improves the delivery of bioactive compounds that promotes healthy ingestion methods, lowers overall dosing, and higher effectiveness in active molecule delivery. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and various cannabinoids. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 27 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lexaria Bioscience’s mission is to provide disruptive technology and become a global leader in altering the delivery of bioactive compounds.

Our vision is to improve upon current delivery technologies and create a transformative platform for delivering biologics and drugs, potentially increasing bioavailability, safety, and patient acceptance.

Lexaria Bioscience was the recipient of the 2018 “Innovator of the Year” Award from the British Columbia Technology Industry Association. In addition, the Company’s Chief Scientific Officer received the “Biotech Entrepreneur Award” from Pro Bioscience International in 2016.